The Supreme Court will consider whether to restrict access to a widely used abortion drug, mifepristone, focusing on the FDA's authority.
Challengers argue that the FDA did not do enough to study the safety implications of the drug when it approved its use and made it more easily accessible in subsequent years.
[
add
]
[
|
|
...
]